Quantitative determination of PEG-hirudin in human plasma using a competitive enzyme-linked immunosorbent assay

Thrombosis Research

Volumn 99, Issue 2, 2000, Pages 195-202

  Song, X H ^a   Huhle, G ^a   Wang, L C ^a   Harenberg, J ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Antibody; Anticoagulants; Ecarin clotting time; ELISA; PEG hirudin

Indexed keywords

MACROGOL; RECOMBINANT HIRUDIN;

ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; PLASMA; PRIORITY JOURNAL; QUANTITATIVE ASSAY;

CALIBRATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPARIN; HIRUDINS; HUMANS; PHENPROCOUMON; POLYETHYLENE GLYCOLS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 0034661298     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(00)00246-2     Document Type: Article

References (29)

1. Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res. 74:1994;1-23.
2. Rübsamen K., Hornberger W., Schweden J., Kurfürst M. Pharmacological characteristics of long acting polyethylene glycol-coupled recombinant hirudin. Thromb Haemost. 65:1991;129.
3. Esslinger H.-U., Haas S., Mauer R., Lassmann A., Dübbers K., Müler-Pelzer H. Pharmacodynamic and safety results of PEG-hirudin in healthy volunteers. Thromb Haemost. 77:1997;911-919.
4. Markwardt F., Nowak G., Stürzebecher J., Griessbach U., Walsmann P., Vogel G. Pharmacokinetics and anticoagulant effects of hirudin in man. Thromb Res. 52:1984;160-163.
5. Walenga J.M., Hoppensteadt D., Kza M., Wallock M., Pifarre R., Fareed J. Laboratory assays for the evaluation of recombinant hirudin. Haemostasis. Suppl 1):1991;49-63.
6. Griessbach U., Stürzebecher J., Markwardt F. Assay of hirudin in plasma using a chromogenic thrombin substrate. Thromb Res. 37:1985;347-350.
7. Walenga J.M., Bakhos M., Messmore H.L., Koza M., Wallock M., Orfei E., Fareed J., Pifarre R. Comparison of recombinant hirudin and heparin as an anticoagulant in a cardiopulmonary bypass model. Blood Coagul Fibrinol. 2:1991;105-111.
8. Nowak G., Bucha E. Quantitative determination of hirudin in blood and body fluids. Semin Thromb Haemost. 22:1996;197-202.
9. Spinner S., Stöffler G., Fink E. Quantitative enzyme-linked immunosorbent assay (ELISA) for hirudin. J Immunol Methods. 87:1986;79-83.
10. Spinner S., Scheffauer F., Maschler R., Stöffler G. A hirudin catching ELISA for quantitating the anticoagulant in the biological fluids. Thromb Res. 51:1988;617-625.
11. Iyer L., Adam M., Amiral J., Fareed J., Bermes E. Jr. Development and validation of two enzyme-linked immunosorbent assay (ELISA) methods for recombinant hirudin. Semin Thromb Hemost. 21:1995;184-192.
12. Kemeny D.M. A Practical Guide to ELISA. 1991;Pergamon Press plc, Oxford.
13. Voller A., Bidwell D.E., Bartlett A. Enzyme-immunoassays in diagnostic medicine; Theory and practice. Bull World Health Org. 53:1976;55-56.
14. Bauch H.-J., Ilsemann K., Beeck H., Voss B., Balleisen L. A double antibody sandwich micro- ELISA for measuring human platelet factor 4. Thromb Res. 37:1985;573-582.
15. Verstraete M., Nurmohamed M., Kienast J., Siebeck M., Silling-Engelhardt G., Büller H.R., Hoet B., Bichler J., Close P., on behalf of the European Hirudin in Thrombosis Group Biological effects of recombinant hirudin (CGP 39393) in human volunteers. J Am Coll Cardiol. 22:1993;364-372.
16. Esslinger H.-U., Greger G., Lassmann A., Mauer R. General tolerability and effects on clotting parameters after single i.v. and s.c. bolus administration of recombinant hirudin (LU 52369) in man. Thromb Haemost. 65:1991;1290.
17. Eichler P., Greinacher A. Anti-hirudin antibodies induced by recombinant hirudin in the treatment of patients with heparin-induced thrombocytopenia. Ann Hematol. 72(Suppl 1):1996;20.
18. Song X.H., Huhle G., Wang L.C., Hoffmann U., Harenberg J. Generation of anti-hirudin antibodies in heparin-induced thrombocytopenia patients treated with r-hirudin. Circulation. 101:1999;1528-1532.
19. Close P., Bichler J., Kerry R., Ekman S., Büller H.R., Kienast J., Marbet G.A., Schramm W., Verstraete M. Weak allergenicity of recombinant hirudin CGP 39393 (Revasc) in immunocompetent volunteers. The European Hirudin in Thrombosis Group. Coron Artery Dis. 5:1994;943-949.
20. Markwardt F., Richter M., Walsmann P., Riesener G., Paintz M. Preparation of dextran-bound recombinant hirudin and its pharmacokinetic behaviour. Biomed Biochim Acta. 49:1990;1103-1108.
21. Rübsamen K., Hornberger W. Prevention of early reocclusion after thrombolysis of copper coil-induced thrombi in the canine carotid artery. Comparison of PEG-hirudin and unfractionated hirudin Thromb Haemost. 76:1996;105-110.
22. Iorio A., Agnelli G., Leone M., Melelli P., Renga C., Nenci G.G. Hirudin and PEG-hirudin inhibit clot-bound thrombin more efficaciously than heparin. Ann Hematol. Suppl 1:1993;1819.
23. Hornberger W., Rübsamen K., Schweden J. Prolonged antithrombotic action of a new polyethylenglycol-coupled hirudin (LU 57291) in two rat thrombosis models. Ann Hematol. Suppl 1:1993;20.
24. Laux V., Schweden J., Maurer R., Hornberger W., Rübsamen K. Antithrombotic effect of a new polyethylenglycol-coupled hirudin (LU 57291) in a venous thrombosis model in the rabbit. Correlation with anti-factor IIa activity in plasma. Ann Hematol. 63(Suppl 1):1993;20.
25. Iyer I., Shavit J., Koza M., Calabria R., Moran S., Fareed J. Alteration of pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV 2-lys 47) after repeated intravenous administration in dogs. Thromb Res. 69:1993;59-70.
26. Walenga J.M., Terrell M.R., Koza M.J., Khenkina Y., Fareed J., Pifarre R. PEG-hiridin as anticoagulant in cardiopulmonary bypass. Thromb Haemost. 73:1995;1454.
27. Pötzsch B., Madlener K., Seelig C., Riess C.F., Greinacher A., Müller-Berghaus G. The whole blood ecarin clotting time assay allows rapid and accurate monitoring of the anticoagulant response of r-hirudin during cardiopulmonary bypass. Thromb Haemost. 77:1997;920-925.
28. Harenberg J, Huhle H, Kessler M, Malsch R, Piazolo L, Dübbers K, Esslinger HU. Interaction of combined (overlapping) treatment with PEG-hirudin and heparin in healthy volunteers. Thromb Haemost 1997;(Suppl):PS-2000.
29. Nurmohamed M.T., Berckmans R.J., Morrien-Salomons W.M., Berends F., Hammes W.D., Rijmerse J.J.M.M., Sturk A. Monitoring anticoagulant therapy by activated partial thromboplastin time. Hirudin assessment Thromb Haemost. 72:1994;685-692.